RU2021132455A - NEW SOLID FORMS (2S,3S,4S,5R,6S)-3,4,5-TRIHYDROXY-6-(((4AR,10AR)-7-HYDROXY-1-PROPYL-1,2,3,4,4A ,5,10,10A-OCTAHYDROBENZO[G]QUINOLIN-6-YL)OXY)TETRAHYDRO-2H-PYRAN-2-CARBOXY ACID - Google Patents

Claims (23)

1. Solid form of the compound of formula (Id),

where said solid form is selected from: a) the zwitterion form of the compound (Id); b) an alkali metal salt of a compound of formula (Id) and c) a halogenated salt of a compound of formula (Id). 2. A solid form according to claim 1, wherein said solid form is a crystalline form. 3. Solid form according to any one of paragraphs. 1 and 2, wherein said solid form is selected from the group consisting of zwitterion dihydrate of compound (Id), zwitterion heptahydrate of compound (Id), and potassium salt of compound (Id). 4. Solid form according to any one of paragraphs. 1-3, wherein said solid form is the zwitterion dihydrate of compound (Id) or the potassium salt of compound (Id). 5. Solid form according to any one of paragraphs. 1-4, wherein said solid form is a dihydrate characterized by an X-ray powder diffraction pattern obtained using CuKα1 radiation (λ=1.5406 Å) containing one or more XRPD peaks listed for the dihydrate in Table 2, group (a). 6. Solid form according to any one of paragraphs. 1-5, wherein said solid form is a dihydrate characterized by an X-ray powder diffraction pattern obtained using CuKα1 radiation (λ=1.5406 Å) containing peaks at the following angles 2θ±0.2° 2θ: 10.4, 11 .6, 12.3, and 13.1, and 13.6°. 7. A solid form according to claim 6, wherein said powder x-ray diffraction pattern further comprises one or more peaks selected from the group consisting of peaks at the following angle values 2θ±0.2° 2θ: 14.3, 15.6, 16, 0, 16.8 and 18.5°. 8. Solid form according to any one of paragraphs. 2-7, wherein said solid form is a crystalline form characterized by an X-ray powder diffraction pattern obtained using CuKα1 radiation (λ=1.5406 Å) as essentially depicted in Figure 8a. 9. Solid form according to any one of paragraphs. 1-8, wherein said solid form exhibits a weight loss of approximately 7.6% w/w compared to initial weight when heated from approximately 30°C to approximately 150°C (heating rate 10°C/min), as measured by thermogravimetric analysis. 10. Solid form according to any one of paragraphs. 1-2, wherein said solid form is a potassium salt characterized by an X-ray powder diffraction pattern obtained using CuKα1 radiation (λ=1.5406 Å) containing one or more XRPD peaks listed for the potassium salt in Table 2, group (a ). 11. The solid form according to claim 10, wherein said potassium salt has a crystalline form characterized by XRPD obtained using CuKα1 radiation (λ=1.5406 Å) containing peaks at the following angle values 2θ±0.2° 2θ: 3, 0, 9.0, 12.6, 13.6 and 15.0°. 12. The solid form of claim. 11, where the specified powder x-ray diffraction pattern further contains one or more peaks selected from the group consisting of peaks at the following values of the angle 2θ±0.2° 2θ: 17.1, 18.0, 18, 4, 18.8 and 19.4°. 13. Solid form according to any one of paragraphs. 1-3 and paragraphs. 11-12, said form exhibiting a weight loss of less than about 1% w/w compared to initial weight when heated from about 20°C to about 150°C (heating rate 10°C/min.), as measured by thermogravimetric analysis. 14. Solid form of the compounds of formula (Id) according to any one of paragraphs. 1-13 for use as a drug. 15. Pharmaceutical composition containing a therapeutically effective amount of the solid form of the compounds of formula (Id) according to any one of paragraphs. 1-13 and one or more pharmaceutically acceptable excipients. 16. Solid form of the compounds of formula (Id) according to any one of paragraphs. 1-13 for use in the treatment of a neurodegenerative disease or disorder such as Parkinson's disease, Huntington's disease, restless leg syndrome, or Alzheimer's disease; or a neuropsychiatric disease or disorder such as schizophrenia, attention deficit hyperactivity disorder, or drug addiction. 17. A method of treating a neurodegenerative disease or disorder such as Parkinson's disease, Huntington's disease, restless leg syndrome, or Alzheimer's disease; or a neuropsychiatric disease or disorder such as schizophrenia, attention deficit hyperactivity disorder or drug addiction; this method includes the introduction of a therapeutically effective amount of the solid form of the compounds of formula (Id) according to any one of paragraphs. 1-13 to a patient in need of it. 18. The use of a solid form of a compound of formula (Id) according to any one of paragraphs. 1-13 in the manufacture of a medicament for the treatment of a neurodegenerative disease or disorder such as Parkinson's disease, Huntington's disease, restless leg syndrome, or Alzheimer's disease; or for the treatment of a neuropsychiatric disease or disorder such as schizophrenia, attention deficit hyperactivity disorder or drug addiction.